إپراتروپيوم بروميد/سالبوتامول

(تم التحويل من Ipratropium bromide/salbutamol)
إپراتروپيوم بروميد/سالبوتامول
Combination of
Ipratropium bromideMuscarinic antagonist
SalbutamolShort-acting β2-adrenergic agonist
البيانات السريرية
الأسماء التجاريةCombivent, DuoNeb, Breva, others
AHFS/Drugs.comFDA Professional Drug Information
فئة السلامة
أثناء الحمل
مسارات
الدواء		Inhalation
رمز ATC
الحالة القانونية
الحالة القانونية
  • AU: S3 (Pharmacist only)
  • UK: POM (Prescription only)
  • US: ℞-only
المعرفات
CompTox Dashboard (EPA)
ECHA InfoCard100.040.779 Edit this at Wikidata
  (verify)

إپراتروپيوم/سالبوتامول، يُباع تحت الاسم التجاري كومبيڤنت Combivent، هو combination medication used to treat chronic obstructive pulmonary disease (COPD).[2][3] It contains ipratropium (an anticholinergic) and salbutamol (albuterol, a β2-adrenergic agonist).[2] It is taken by inhalation.[4]

Common side effects include sore throat, muscle cramps, and nausea.[2] Other side effects may include bronchospasm, allergic reactions, and upper respiratory tract infections.[2] Safety in pregnancy is unclear.[1] Each medication typically decreases bronchospasm and does so via different mechanisms.[2]

The combination was approved for medical use in the United States in 1996.[4] It is available as a generic medication.[3] Sixty doses in the United Kingdom costs the NHS about 18 £ as of 2019.[3] In the United States the wholesale cost of this amount is about US$9.50.[5] In 2016 it was the 166th most prescribed medication in the United States with more than 3 million prescriptions.[6]

المجتمع والثقافة

Since Combivent contains a chlorofluorocarbon based propellant, it is being phased out in European Union countries. Chloroflourocarbons (CFC) are attributed to depletion of the ozone layer.

المصادر

  1. ^ أ ب "Albuterol / ipratropium Use During Pregnancy". Drugs.com (in الإنجليزية). Retrieved 19 April 2019.
  2. ^ أ ب ت ث ج "DailyMed - ipratropium bromide and albuterol sulfate inhalant". dailymed.nlm.nih.gov. Retrieved 18 April 2019.
  3. ^ أ ب ت British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 247. ISBN 9780857113382.
  4. ^ أ ب "Ipratropium and Albuterol - FDA prescribing information, side effects and uses". Drugs.com (in الإنجليزية). Retrieved 18 April 2019.
  5. ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services (in الإنجليزية). Retrieved 3 March 2019.
  6. ^ "The Top 300 of 2019". clincalc.com. Retrieved 22 December 2018.

وصلات خارجية

  • DailyMed
  • Consumer Medication Information from PubMed
  • National Asthma Education and Prevention Program Expert Panel 3. Expert panel report 3: guidelines for the diagnosis and management of asthma. Bethesda (MD): National Institutes of Health. National Heart, Lung, and Blood Institute; 2007 Aug. NIH Publication No. 07-4051.
?
تمّ الاسترجاع من "https://www.marefa.org/w/index.php?title=إپراتروپيوم_بروميد/سالبوتامول&oldid=2237278"